Cargando…

Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer

BACKGROUND: Metastatic pancreatic cancer (mPC) is a highly lethal malignancy with poorer survival. However, chemotherapy alone was unable to maintain long‐term survival. This study aimed to evaluate the individualized survival benefits of pancreatectomy plus chemotherapy (PCT) for mPC. METHODS: A to...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Duorui, Lai, Guihua, An, Guilin, Wu, Zhuojun, Lei, Shujun, Li, Jing, Cao, Jianxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481362/
https://www.ncbi.nlm.nih.gov/pubmed/34604055
http://dx.doi.org/10.3389/fonc.2021.719253
_version_ 1784576668736684032
author Nie, Duorui
Lai, Guihua
An, Guilin
Wu, Zhuojun
Lei, Shujun
Li, Jing
Cao, Jianxiong
author_facet Nie, Duorui
Lai, Guihua
An, Guilin
Wu, Zhuojun
Lei, Shujun
Li, Jing
Cao, Jianxiong
author_sort Nie, Duorui
collection PubMed
description BACKGROUND: Metastatic pancreatic cancer (mPC) is a highly lethal malignancy with poorer survival. However, chemotherapy alone was unable to maintain long‐term survival. This study aimed to evaluate the individualized survival benefits of pancreatectomy plus chemotherapy (PCT) for mPC. METHODS: A total of 4546 patients with mPC from 2004 to 2015 were retrieved from the Surveillance, Epidemiology, and End Results database. The survival curve was calculated using the Kaplan-Meier method and differences in survival curves were tested using log-rank tests. Cox proportional hazards regression analyses were performed to evaluate the prognostic value of involved variables. A new nomogram was constructed to predict overall survival based on independent prognosis factors. The performance of the nomogram was measured by concordance index, calibration plot, and area under the receiver operating characteristic curve. RESULTS: Compared to pancreatectomy or chemotherapy alone, PCT can significantly improve the prognosis of patients with mPC. In addition, patients with well/moderately differentiated tumors, age ≤66 years, tumor size ≤42 mm, or female patients were more likely to benefit from PCT. Multivariate analysis showed that age at diagnosis, sex, marital status, grade, tumor size, and treatment were independent prognostic factors. The established nomogram has a good ability to distinguish and calibrating. CONCLUSION: PCT can prolong survival in some patients with mPC. Our nomogram can individualize predict OS of pancreatectomy combined with chemotherapy in patients with concurrent mPC.
format Online
Article
Text
id pubmed-8481362
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84813622021-10-01 Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer Nie, Duorui Lai, Guihua An, Guilin Wu, Zhuojun Lei, Shujun Li, Jing Cao, Jianxiong Front Oncol Oncology BACKGROUND: Metastatic pancreatic cancer (mPC) is a highly lethal malignancy with poorer survival. However, chemotherapy alone was unable to maintain long‐term survival. This study aimed to evaluate the individualized survival benefits of pancreatectomy plus chemotherapy (PCT) for mPC. METHODS: A total of 4546 patients with mPC from 2004 to 2015 were retrieved from the Surveillance, Epidemiology, and End Results database. The survival curve was calculated using the Kaplan-Meier method and differences in survival curves were tested using log-rank tests. Cox proportional hazards regression analyses were performed to evaluate the prognostic value of involved variables. A new nomogram was constructed to predict overall survival based on independent prognosis factors. The performance of the nomogram was measured by concordance index, calibration plot, and area under the receiver operating characteristic curve. RESULTS: Compared to pancreatectomy or chemotherapy alone, PCT can significantly improve the prognosis of patients with mPC. In addition, patients with well/moderately differentiated tumors, age ≤66 years, tumor size ≤42 mm, or female patients were more likely to benefit from PCT. Multivariate analysis showed that age at diagnosis, sex, marital status, grade, tumor size, and treatment were independent prognostic factors. The established nomogram has a good ability to distinguish and calibrating. CONCLUSION: PCT can prolong survival in some patients with mPC. Our nomogram can individualize predict OS of pancreatectomy combined with chemotherapy in patients with concurrent mPC. Frontiers Media S.A. 2021-09-16 /pmc/articles/PMC8481362/ /pubmed/34604055 http://dx.doi.org/10.3389/fonc.2021.719253 Text en Copyright © 2021 Nie, Lai, An, Wu, Lei, Li and Cao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Nie, Duorui
Lai, Guihua
An, Guilin
Wu, Zhuojun
Lei, Shujun
Li, Jing
Cao, Jianxiong
Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer
title Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer
title_full Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer
title_fullStr Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer
title_full_unstemmed Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer
title_short Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer
title_sort individualized prediction of survival benefits of pancreatectomy plus chemotherapy in patients with simultaneous metastatic pancreatic cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481362/
https://www.ncbi.nlm.nih.gov/pubmed/34604055
http://dx.doi.org/10.3389/fonc.2021.719253
work_keys_str_mv AT nieduorui individualizedpredictionofsurvivalbenefitsofpancreatectomypluschemotherapyinpatientswithsimultaneousmetastaticpancreaticcancer
AT laiguihua individualizedpredictionofsurvivalbenefitsofpancreatectomypluschemotherapyinpatientswithsimultaneousmetastaticpancreaticcancer
AT anguilin individualizedpredictionofsurvivalbenefitsofpancreatectomypluschemotherapyinpatientswithsimultaneousmetastaticpancreaticcancer
AT wuzhuojun individualizedpredictionofsurvivalbenefitsofpancreatectomypluschemotherapyinpatientswithsimultaneousmetastaticpancreaticcancer
AT leishujun individualizedpredictionofsurvivalbenefitsofpancreatectomypluschemotherapyinpatientswithsimultaneousmetastaticpancreaticcancer
AT lijing individualizedpredictionofsurvivalbenefitsofpancreatectomypluschemotherapyinpatientswithsimultaneousmetastaticpancreaticcancer
AT caojianxiong individualizedpredictionofsurvivalbenefitsofpancreatectomypluschemotherapyinpatientswithsimultaneousmetastaticpancreaticcancer